Penumbra Competitors

Baxter International (NYSE:BAX) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Baxter International and Penumbra, as provided by MarketBeat.

Baxter International presently has a consensus price target of $92.2667, indicating a potential upside of 18.76%. Penumbra has a consensus price target of $279.00, indicating a potential downside of 1.91%. Given Baxter International's higher probable upside, equities analysts plainly believe Baxter International is more favorable than Penumbra.

Volatility and Risk

Baxter International has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Baxter International and Penumbra's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Baxter International and Penumbra's top-line revenue, earnings per share (EPS) and valuation.

Baxter International has higher revenue and earnings than Penumbra. Baxter International is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.9% of Baxter International shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 0.1% of Baxter International shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Baxter International beats Penumbra on 10 of the 14 factors compared between the two stocks.

DexCom (NASDAQ:DXCM) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares DexCom and Penumbra's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares DexCom and Penumbra's top-line revenue, earnings per share (EPS) and valuation.

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DexCom has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for DexCom and Penumbra, as provided by MarketBeat.

DexCom presently has a consensus price target of $430.3750, indicating a potential upside of 8.19%. Penumbra has a consensus price target of $279.00, indicating a potential downside of 1.91%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Penumbra.

Institutional and Insider Ownership

94.1% of DexCom shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 0.7% of DexCom shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

DexCom beats Penumbra on 13 of the 14 factors compared between the two stocks.

ResMed (NYSE:RMD) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares ResMed and Penumbra's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ResMed and Penumbra's gross revenue, earnings per share and valuation.

ResMed has higher revenue and earnings than Penumbra. ResMed is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ResMed has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ResMed and Penumbra, as reported by MarketBeat.com.

ResMed currently has a consensus target price of $189.40, indicating a potential downside of 1.75%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than Penumbra.

Insider & Institutional Ownership

68.6% of ResMed shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 1.3% of ResMed shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ResMed beats Penumbra on 8 of the 13 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Teleflex and Penumbra's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Teleflex and Penumbra's gross revenue, earnings per share and valuation.

Teleflex has higher revenue and earnings than Penumbra. Teleflex is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teleflex has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Teleflex and Penumbra, as reported by MarketBeat.com.

Teleflex currently has a consensus target price of $433.60, indicating a potential upside of 8.91%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given Teleflex's stronger consensus rating and higher probable upside, analysts clearly believe Teleflex is more favorable than Penumbra.

Insider & Institutional Ownership

89.8% of Teleflex shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Teleflex beats Penumbra on 13 of the 15 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk and Volatility

Insulet has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Insulet and Penumbra, as reported by MarketBeat.com.

Insulet currently has a consensus target price of $246.50, indicating a potential downside of 4.86%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Insulet.

Profitability

This table compares Insulet and Penumbra's net margins, return on equity and return on assets.

Insider & Institutional Ownership

88.2% of Penumbra shares are owned by institutional investors. 1.1% of Insulet shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Insulet and Penumbra's gross revenue, earnings per share and valuation.

Penumbra has lower revenue, but higher earnings than Insulet. Penumbra is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

Insulet beats Penumbra on 8 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and NovoCure (NASDAQ:NVCR) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Penumbra and NovoCure, as reported by MarketBeat.

Penumbra currently has a consensus target price of $279.00, indicating a potential downside of 1.91%. NovoCure has a consensus target price of $126.00, indicating a potential downside of 15.49%. Given Penumbra's stronger consensus rating and higher possible upside, equities analysts plainly believe Penumbra is more favorable than NovoCure.

Profitability

This table compares Penumbra and NovoCure's net margins, return on equity and return on assets.

Insider and Institutional Ownership

88.2% of Penumbra shares are held by institutional investors. Comparatively, 71.1% of NovoCure shares are held by institutional investors. 8.9% of Penumbra shares are held by insiders. Comparatively, 5.1% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Penumbra and NovoCure's gross revenue, earnings per share and valuation.

Penumbra has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats NovoCure on 7 of the 13 factors compared between the two stocks.